The Mumbai-based Ajanta Pharmaceuticals (APL) has launched its once-a-day 200mg controlled release nimesulide brand Nimlodi for arthritis. Nimlodi, which was developed by the Company through new drug delivery system, is the world's first once-a-day nimesulide brand for the treatment of arthritis. Ajanta, which manufactures both Allopathic and Ayurvedic medicines, developed this oral formulation in its fully integrated research and development centre at Kandivali in Mumbai.
Since the brand received marketing approval from the Drug Controller General of India last month, it has been manufactured at Ajanta's Aurangabad factory. Nimlodi is marketed under the Ethicare division of Ajanta and the Company has already filed a patent application for the product. Nimlodi becomes the second most important product in the Ajanta portfolio after Carofit for which it has a global patent. Currently, the nimesulide market in India is worth Rs. 200 crore.
Ajanta, which has been conducting aggressive research for development of novel oral products and improved formulations, is looking for international partnerships in marketing the product all over the world.